102 related articles for article (PubMed ID: 12568610)
21. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin S, but not cathepsin L, participates in the MHC class II-associated invariant chain processing in large yellow croaker (Larimichthys crocea).
Li Q; Ao J; Mu Y; Yang Z; Li T; Zhang X; Chen X
Fish Shellfish Immunol; 2015 Dec; 47(2):743-50. PubMed ID: 26475363
[TBL] [Abstract][Full Text] [Related]
23. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
24. Proteases, processing, and thymic selection.
Cresswell P
Science; 1998 Apr; 280(5362):394-5. PubMed ID: 9575085
[No Abstract] [Full Text] [Related]
25. Anti-cathepsin L monoclonal antibodies that distinguish cathepsin L from cathepsin V.
Kopitar-Jerala N; Bevec T; Barlic-Maganja D; Gubensek F; Turk V
Biol Chem; 2001 May; 382(5):867-70. PubMed ID: 11517943
[TBL] [Abstract][Full Text] [Related]
26. Improvement of cathepsin S detection using a designed FRET peptide based on putative natural substrates.
Oliveira M; Torquato RJ; Alves MF; Juliano MA; Brömme D; Barros NM; Carmona AK
Peptides; 2010 Apr; 31(4):562-7. PubMed ID: 20045715
[TBL] [Abstract][Full Text] [Related]
27. Immunological significances of invariant chain from the aspect of its structural homology with the cystatin family.
Katunuma N; Kakegawa H; Matsunaga Y; Saibara T
FEBS Lett; 1994 Aug; 349(2):265-9. PubMed ID: 8050579
[TBL] [Abstract][Full Text] [Related]
28. Exogenous Thyropin from p41 Invariant Chain Diminishes Cysteine Protease Activity and Affects IL-12 Secretion during Maturation of Human Dendritic Cells.
Zavašnik-Bergant T; Bergant Marušič M
PLoS One; 2016; 11(3):e0150815. PubMed ID: 26960148
[TBL] [Abstract][Full Text] [Related]
29. A new triple-stranded alpha-helical bundle in solution: the assembling of the cytosolic tail of MHC-associated invariant chain.
Motta A; Amodeo P; Fucile P; Castiglione Morelli MA; Bremnes B; Bakke O
Structure; 1997 Nov; 5(11):1453-64. PubMed ID: 9384561
[TBL] [Abstract][Full Text] [Related]
30. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
[TBL] [Abstract][Full Text] [Related]
31. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators.
Somoza JR; Palmer JT; Ho JD
J Mol Biol; 2002 Sep; 322(3):559-68. PubMed ID: 12225749
[TBL] [Abstract][Full Text] [Related]
32. The contribution of N-terminal region residues of cystatin A (stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B, and cathepsin L.
Estrada S; Pavlova A; Björk I
Biochemistry; 1999 Jun; 38(22):7339-45. PubMed ID: 10353845
[TBL] [Abstract][Full Text] [Related]
33. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii.
Jasanoff A; Wagner G; Wiley DC
EMBO J; 1998 Dec; 17(23):6812-8. PubMed ID: 9843486
[TBL] [Abstract][Full Text] [Related]
34. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
35. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
36. Invariant chain controls the activity of extracellular cathepsin L.
Fiebiger E; Maehr R; Villadangos J; Weber E; Erickson A; Bikoff E; Ploegh HL; Lennon-Duménil AM
J Exp Med; 2002 Nov; 196(9):1263-9. PubMed ID: 12417635
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of major histocompatibility complex class II compartments in cortical thymic epithelial cells.
Arudchelvan Y; Nishimura Y; Tokuda N; Sawada T; Ueyama Y; Fukumoto T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Sep; 274(1):798-806. PubMed ID: 12923890
[TBL] [Abstract][Full Text] [Related]
38. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain.
Yoshiyama Y; Arai K; Oki T; Hattori T
Neurosci Lett; 2000 Aug; 290(2):125-8. PubMed ID: 10936693
[TBL] [Abstract][Full Text] [Related]
39. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
40. Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain.
Jasanoff A; Park SJ; Wiley DC
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9900-4. PubMed ID: 7568241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
